by Richard Daverman, PhD
December 11, 2012 -- Shanghai Fosun Pharma and Dalian Wanchun Biotech will establish a JV to develop innovative oncology treatments. Wanchun has in-licensed China rights to plinabulin, a Class 1.1 innovative anti-tumor drug from Nereus Pharma of the US. Through the JV, Fosun will build Wanchun’s development ability and add potential drugs to its pipeline. Wanchun will serve as an innovative drug incubator for Fosun. More details....
Stock Symbols: (SHA: 600196; HK: 2196)
